TY - JOUR
T1 - New strategies in colorectal cancer
T2 - Biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways
AU - Dasari, Arvind
AU - Messersmith, Wells A.
PY - 2010/8/1
Y1 - 2010/8/1
N2 - Initial experience with the epidermal growth factor receptor monoclonal antibodies (EGFR MoAb) in unselected patients with metastatic colorectal cancer (mCRC) showed that most of the treated patients did not derive therapeutic benefit. This outcome has driven the search for biomarkers for this population. Recent advances have further shown the heterogeneous nature of this disease with multiple interlinked pathways being implicated. Two such pathways downstream to the EGFR, mitogen-activated protein kinase (MAPK) and (phosphoinositide 3-kinase) PI3K, have gained increasing attention and become targets for development of novel biomarkers and therapeutic agents. Here, we highlight recent progress.
AB - Initial experience with the epidermal growth factor receptor monoclonal antibodies (EGFR MoAb) in unselected patients with metastatic colorectal cancer (mCRC) showed that most of the treated patients did not derive therapeutic benefit. This outcome has driven the search for biomarkers for this population. Recent advances have further shown the heterogeneous nature of this disease with multiple interlinked pathways being implicated. Two such pathways downstream to the EGFR, mitogen-activated protein kinase (MAPK) and (phosphoinositide 3-kinase) PI3K, have gained increasing attention and become targets for development of novel biomarkers and therapeutic agents. Here, we highlight recent progress.
UR - http://www.scopus.com/inward/record.url?scp=77955122376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955122376&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-09-2283
DO - 10.1158/1078-0432.CCR-09-2283
M3 - Review article
C2 - 20554751
AN - SCOPUS:77955122376
SN - 1078-0432
VL - 16
SP - 3811
EP - 3818
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 15
ER -